![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
University of Rostock MSD Sharp & Dohme GmbH |
---|---|
Information provided by: | University of Rostock |
ClinicalTrials.gov Identifier: | NCT00414739 |
The study analysis the influence of benzalkonium chloride on the density of antigen presenting Langerhans cells. This is achieved in a double blind randomized study using in-vivo confocal microscopy to identify and quantify Langerhans cells of the human cornea in its central and peripheral part. This study design is based on observations with raised Langerhans cell density after the application of benzalkonium chloride containing eye drops in glaucoma patients.
Condition | Intervention | Phase |
---|---|---|
Eye Diseases |
Drug: Benzalkonium chloride |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety Study |
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Germany | |
University of Rostock, Eye Department | Recruiting |
Rostock, Germany, 18057 | |
Contact: Rudolf F. Guthoff, Prof. Dr. +49/(0)381/4948501 rudolf.guthoff@med.uni-rostock.de | |
Principal Investigator: Andrey Zhivov, Dr. med. |
Study Chair: | Rudolf F. Guthoff, Prof. Dr. | University of Rostock, Eye Department |
Study ID Numbers: | BAC-2006-1 |
Study First Received: | December 21, 2006 |
Last Updated: | December 21, 2006 |
ClinicalTrials.gov Identifier: | NCT00414739 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
growth of dendritic cells prevention |
Eye Diseases Benzalkonium Compounds |
Anti-Infective Agents Anti-Infective Agents, Local Therapeutic Uses Pharmacologic Actions |